EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 1st, 2022 • Neoleukin Therapeutics, Inc. • Pharmaceutical preparations • Washington
This Executive Employment Agreement (the “Agreement”), made between Neoleukin Therapeutics, Inc., a Delaware corporation (the “Company”), and Priti Patel (the “Executive” and, collectively with the Company, the “Parties”), is entered into as of April 14, 2021, to be effective as of the Effective Date (as defined below).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. AMENDMENT NO. 2 TO EXCLUSIVE START- UP LICENSE...Exclusive Start-Up License Agreement • March 1st, 2022 • Neoleukin Therapeutics, Inc. • Pharmaceutical preparations
This Amendment No. 2 to the Exclusive Start-Up License Agreement (this “Amendment No. 2”) effective as of December 15, 2021 (the “Amendment No. 2 Effective Date”), is entered into between the University of Washington (“University”), and Neoleukin Therapeutics, Inc. (“Company”). “Party” or “Parties” shall mean, individually, University or Company as the context requires and, collectively, both University and Company.
